According to the World Health Organization, cardiovascular diseases (CVDs), including coronary artery heart disease, cerebrovascular diseases, rheumatic heart disease, and other related conditions, are the leading cause of death worldwide, with an estimated 17.9 million deaths annually [1]. CVD can be prevented in various ways, particularly for those with mild conditions or who do not require essential drug treatment. Managing risk factors through healthy eating habits and regular exercise is crucial for CVD prevention. Additionally, appropriately treating or preventing factors that can lead to CVD, such as obesity, diabetes, high cholesterol, and hypertension, is also beneficial. Biomarkers for assessing CVDs include N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, and cardiac troponin (cTn), which appear in the blood when heart muscle cells are damaged [2]. Various biomarkers for CVDs have been identified, including inflammatory cytokines that swerve as useful biomarkers for heart failure and coronary artery disease owing to the close association between inflammation and CVD [2, 3]. These biomarkers play a crucial role in diagnosis and risk assessment. However, additional data are needed before these cytokines can be reliably used in clinical practice; for now, they serve primarily as reference indicators in clinical diagnosis.

The consumption of vegetables and fruits rich in antioxidants and fiber helps manage factors that contribute to CVDs [3]. Unsaturated fatty acids found in olive oil and nuts can help prevent CVDs by regulating cholesterol metabolism. Additionally, improving the diet by reducing salt intake and limiting processed foods can also help mitigate risk factors for CVD [3]. Polyphenols in vegetables, fruits, and various plants prevent CVD by reducing oxidative stress through antioxidant activity, inhibiting pro-inflammatory cytokines, and promoting vasodilation [3]. Additionally, various plant-derived components, such as dietary fiber, vitamins, fatty acids, and caffeine, have also been shown to prevent CVD [4].

The fruit of the cacao tree (Theobroma cacao) is the primary raw material in chocolate. Theobroma cacao is a tropical plant originating from South America that is widely cultivated across West Africa and Asia [5]. Cacao refers to the unprocessed state of the cacao tree, cacao pods, and cacao beans. When processed into powder, it is called cacao, and products made by mixing it with other ingredients are referred to as chocolate [5]. Cacao fruit has numerous benefits [5, 6]. For example, cacao is rich in polyphenols, which are powerful antioxidants that prevent CVDs by improving cholesterol levels and managing hypertension [6]. Additionally, cacao contains fiber and unsaturated fatty acids, which can aid in preventing CVDs [7]. However, comprehensive reviews summarizing the recently reported CVD-preventive effects of cacao and its underlying mechanisms from in vitro, in vivo, and clinical studies are currently lacking.

In this review, we aim to analyze the trends in research regarding the CVD-preventive effects of cacao and chocolate, explore their mechanisms of action in the human body, and present their potential as functional ingredients. Furthermore, this review examines how these findings can inform the development of technologies and products aligned with future trends in cacao and chocolate.

The chemical composition of cacao varies depending on its variety and growing conditions, which directly influence its nutrient profile and potential health benefits [7]. Cacao beans are extracted from their pods and undergo fermentation and drying after harvesting [7]. Once processed, they are transported to chocolate production facilities, where they are roasted and winnowed to remove their shells. According to the Codex Alimentarius, cacao products should contain no more than 5% shell content [7, 8]. Previously, cacao pods and bean shells were considered waste, with only approximately 10% of the cacao fruit used for commercial purposes [7, 8, 9]. However, cacao bean shells (CBSs) possess a nutrient profile similar to that of cacao beans, although with a lower fat content and higher dietary fiber levels [7, 10, 11, 12]. The dietary fiber in CBS is primarily composed of pectic polysaccharides, cellulose, and hemicelluloses, which support intestinal health, help reduce cholesterol levels, and aid in regulating glucose absorption [10]. Additionally, cacao byproducts are rich in bioactive compounds, such as polyphenols, which offer various health benefits [13].

The beans of Theobroma species exhibit a diverse chemical composition, playing a key role in determining the nutritional value and sensory characteristics of their final products [14, 15]. Polyphenols are particularly important, contributing to the characteristic bitterness and astringency of cacao [14, 16]. Furthermore, specific chemical constituents, such as reducing sugars, free amino acids, and peptides, influence the formation of flavor compounds during post-harvest processing [17].

Cacao pods exhibit significant bioactive and antioxidant properties, likely attributable to their phytochemical composition, which closely resembles that of cacao beans [18, 19]. Their potential for incorporation into dietary applications has been widely studied, highlighting their value as a source of bioactive compounds, particularly in the plant industry [18]. Additionally, multiple studies have reported their pharmacological benefits, including antioxidant and antifungal activities [10, 20]. As a byproduct of cacao production, the husk accounts for approximately 67–76% of the total wet weight of the cacao pod and has historically been regarded as a non-consumable residue [20, 21].

CBSs comprise proteins, lipids, carbohydrates, moisture, and ash. CBSs also contain polyphenols, especially flavonoids, such as catechins and procyanidins, which provide antioxidant, anti-inflammatory, and other potential health benefits [8, 10]. The total phenolic content varies significantly depending on the extraction method and environmental factors, and the polyphenols in CBSs are sensitive to processing conditions, such as roasting and drying. CBSs also contain key methylxanthines, namely theobromine and caffeine, which are generated during cacao fermentation [22]. Theobromine, present in higher amounts than caffeine, has mild effects on the central nervous system and offers benefits, such as muscle relaxation, cardiac stimulation, and potential use, as a bronchodilator [22, 23]. Caffeine acts as a stimulant but may have adverse effects when consumed in excess [22, 24]. Furthermore, methylxanthines in CBSs enhance the bioavailability of cacao flavanols, thereby contributing to cardiovascular health. The moderate caffeine content and methylxanthines derived from CBSs enhance the value of this byproduct owing to their potential health benefits [10, 18, 24]. CBSs are also rich in minerals, particularly potassium, magnesium, calcium, and phosphorus, which are found in higher amounts in CBS than in cacao nibs owing to their accumulation in the outer shell [10]. Additionally, fermentation with specific fungi enhances mineral content. However, mineral levels vary depending on the geographic origin and soil composition where the plant was grown [10, 25]. CBSs are also a source of vitamin D, which is formed during fermentation through light activation of ergosterol. For example, CBS-fed cows produced butter with increased vitamin D levels [10, 25]. Additionally, CBSs contain notable amounts of vitamins B1 and B2, with trace amounts of vitamins B6 and D, but no detectable vitamin C. They also contain vitamin E in the form of various tocopherols, further enhancing their nutritional value [10, 11, 25]. A summary of the chemical composition of cacao beans, shells, and pods is presented in Table 1 (Ref. [10, 11, 12, 14, 15, 18, 19]).

CVDs are characterized by the hardening or narrowing of blood vessels and the formation of blood clots. The incidence of these conditions increases due to excessive stress, irregular eating habits, and lack of exercise [1, 26]. Especially during the early stages, CVDs often remain asymptomatic or present with mild physical discomfort, contributing to underdiagnosis and delayed treatment [1, 26, 27]. However, sudden events, such as heart attacks, strokes, or heart failure, can result in immediate death. CVDs are not limited to specific age groups, sexes, or social backgrounds and are not confined solely to those of advanced age [1, 26, 27].

Regular health check-ups are particularly important for individuals with risk factors, such as hypertension, diabetes, or a family history of CVDs, as these can help in diagnosing and treating the condition [26, 27]. Methods for diagnosing CVDs include blood pressure measurement, echocardiograms, cardiovascular computed tomography scans, and electrocardiograms [26, 27]. Biochemical blood tests can also directly measure heart damage using markers, such as NT-proBNP, cTn, and creatine kinase MB (CK-MB) [2, 3, 26, 27]. NT-proBNP is secreted by myocardial cells in the ventricles in response to increased ventricular volume or overload, leading to elevated levels in the bloodstream [2, 3]. Consequently, NT-proBNP is useful for diagnosing, managing, and assessing the risk of ventricular dysfunction through blood tests [2, 3, 26, 27]. Troponin, a muscle protein complex found in striated muscle, comprises troponin C, T, and I [2, 3, 26, 27]. All troponin isoforms are present in both skeletal and cardiac muscles; however, cardiac troponin T and I are specific to the heart [2, 3]. When myocardial cells are damaged, troponin is released into the bloodstream, making blood tests crucial for diagnosing heart damage [2, 3, 26, 27]. CK-MB is an isoenzyme of creatine kinase predominantly localized in the cardiac muscle. Upon muscle damage, CK-MB is released into the bloodstream, resulting in elevated levels of this isoenzyme [2, 28]. CK-MB is commonly used to diagnose acute myocardial infarction and myocarditis.

Several other factors that may also contribute to the development of CVDs have been measured and analyzed. For instance, lipid accumulation, inflammatory responses, and oxidative stress in blood vessels can be measured to assess atherosclerotic CVD [29]. Specifically, measurements of low-density lipoprotein (LDL), high-density lipoprotein, the apolipoproteinB/A ratio, C-reactive protein (CRP), and reactive oxygen species (ROS) can help predict heart damage [29]. These biomarkers can provide an early indication of potential problems during screening, often at relatively low costs. However, accurate diagnosis requires biochemical blood analyses and additional diagnostic methods to confirm the condition.

Recent advancements in analytical technologies have led to the discovery of various metabolites, and their use in diagnostics enhances the accuracy of risk prediction [30]. Particularly, lipid-related metabolic profiles and their metabolic pathways are crucial for assessing CVD risk. Dyslipidemia and alterations in lipid metabolism are associated with abnormalities in fatty acid metabolism and mitochondrial dysfunction [30]. For example, acylcarnitine, a metabolite involved in regulating energy and fatty acid metabolism, plays an essential role in maintaining energy homeostasis in the myocardium [30]. Abnormal levels of acylcarnitine are associated with disturbances in myocardial regulation, indicating potential heart dysfunction. This highlights the importance of studying metabolic pathways and their markers in improving the precision of CVD risk assessments [30, 31].

The bioactive compounds of cacao offer beneficial effects on human health, particularly in relation to CVDs [6, 7, 32]. Cacao byproducts, particularly CBSs, have multiple beneficial cardiovascular effects in vitro [10]. Notably, CBSs bind bile salts and cholesterol during digestion, potentially reducing cholesterol absorption and contributing to improved lipid profiles [33]. Additionally, CBSs demonstrate inhibitory activity against lipase, which may lower lipid levels, indicating a beneficial hypolipidemic effect on cardiovascular health [34, 35]. CBSs also possess significant antioxidant capabilities as they are rich in polyphenolic compounds, such as catechin, epicatechin, and quercetin [36]. These polyphenols neutralize free radicals, thereby reducing oxidative stress—a critical factor in the development of CVDs—and also exhibit anti-inflammatory properties, further supporting cardiovascular health [37, 38, 39]. Additionally, CBSs contain substantial dietary fiber, which can bind cholesterol and bile acids, potentially lowering blood cholesterol and improving lipid profiles, thereby reducing cardiovascular risk [35].

Cacao pods have shown promising cardiovascular benefits through several in vitro mechanisms [40]. Extracts from cacao pods inhibit enzymes associated with hypertension and hyperuricemia, notably angiotensin-converting enzyme (ACE), which is crucial for blood pressure regulation, and xanthine oxidase (XO), involved in uric acid production. Furthermore, cacao extracts have demonstrated ACE inhibitory activity in endothelial and smooth muscle cell cultures, contributing to reduced angiotensin-II-mediated vasoconstriction [41]. These findings suggest potential roles in managing hypertension and reducing cardiovascular risk [42]. Rich in flavonoids and phenolic acids, cacao pods possess significant antioxidant activity, neutralizing free radicals and reducing oxidative stress associated with CVDs [43]. Furthermore, cacao pod extracts inhibit $\alpha$-amylase, an enzyme crucial for carbohydrate digestion. This inhibition may help to regulate postprandial blood glucose levels, offering cardiovascular protection, which is particularly relevant for individuals with diabetes [44, 45].

Rich in polyphenols, particularly flavanols, such as catechins and procyanidins, cacao beans possess strong antioxidant activities, reducing oxidative stress associated with CVDs. Additionally, cacao polyphenols modulate inflammatory markers associated with atherosclerosis, such as interleukins and Tumor necrosis factor-alpha (TNF-$\alpha$), potentially hindering disease progression by reducing inflammation [46]. A summary of the in vitro efficacy and mechanisms of action of cacao beans, shells, and pods is presented in Table 2 (Ref. [34, 36, 37, 38, 39, 42, 43, 44, 45, 47, 48, 49, 50, 51]).

In vivo studies consistently show that cacao and its bioactive components—particularly polyphenols, epicatechin, procyanidins, and theobromine—provide cardioprotective effects via anti-inflammatory, antioxidant, vasodilatory, and antihypertensive pathways. In a murine ischemia-reperfusion model, phenolic-rich cacao extracts (5–25 mg/kg) reduced lipid peroxidation, nitro-oxidative stress, and inflammatory markers [interleukin 6 (IL-6), nuclear factor kappa B (NF-$\kappa$B)], while upregulating AKT Serine/Threonine kinase 1 (p-Akt) and extracellular signal-regulated kinase 1/2 (p-Erk1/2 or mitogen-activated protein kinase (MAPK)) signaling [52]. Similarly, when cacao extracts were administered to experimental mice at daily doses of 5–25 mg/kg, they alleviated membrane peroxidation and nitro oxidative stress caused by myocardial injury and decreased the levels of inflammatory biomarkers IL-6 and NF-$\kappa$B. They also increased the activation of cell signaling proteins p-Akt and p-Erk1/2 [52]. In another study, a flavonoid-rich cacao-carob blend was evaluated for cardioprotective properties when administered alone or in combination with metformin using a diabetic cardiomyopathy mouse model [53]. This blend improved glucose homeostasis and alleviated cardiac dysfunction, hypertrophy, and fibrosis. These effects were accompanied by inhibition of intracellular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, reduction in ROS production, and suppression of inflammatory cytokines, resulting from the regulation of sirtuin 1 and nuclear factor E2-related factor 2 (Nrf2) signaling pathways [53]. These findings suggest that the cacao-carob blend can prevent cardiac remodeling and dysfunction associated with diabetes.

In animal models of heart failure, supplementation with cacao bean polyphenols, epicatechin, or procyanidins significantly attenuated cardiac hypertrophy, improved systolic function, and downregulated pro-inflammatory gene expression. These results suggest that polyphenols, epicatechin, and procyanidins exhibit anti-remodeling and anti-inflammatory actions via modulation of cardiac signaling pathways, such as NF-$\kappa$B and MAPK [54]. In systemic models of inflammation, cacao polyphenols reduced circulating levels of CRP, IL-6, and TNF-$\alpha$, key markers involved in atherosclerosis and endothelial dysfunction [55]. In a rat model of isoproterenol-induced acute myocardial injury, pretreatment with cacao extract (100 mg/kg/day, orally for 2 weeks) significantly reduced serum levels of cardiac injury markers, including troponin, lactate dehydrogenase (LDH), and malondialdehyde (MDA), compared with the untreated myocardial infarction group [56]. Additional studies using cacao pod fractions and catechin-enriched extracts reported improvements in vascular function, enhanced nitric oxide (NO) production, and reduced LDL oxidation in rats and mice, indicating a lipid-lowering and vasodilatory mechanism [57]. Hypertensive models, including rats and aged rodents, demonstrated that cacao flavonoids and theobromine lowered blood pressure, suppressed ACE activity, and upregulated endothelial nitric oxide synthase (eNOS) and Nrf2 expression, which are critical for endothelial homeostasis and oxidative stress defense [58, 59]. Cacao-derived peptides also exhibit antihypertensive properties by binding directly to the catalytic domain of ACE, thereby reducing systemic blood pressure in vivo [50]. In pig models, cacao flavonoids attenuated atherosclerosis progression and oxidative damage, reinforcing their protective role in vascular health [60]. Cacao-derived theobromine reduced blood pressure and increased eNOS and Nrf2 expressions in aged hypertensive rats while also improving vascular function and decreasing IL-6 and TNF-$\alpha$ levels in mice [61, 62]. Furthermore, cacao shell extract restored vascular function and decreased inflammatory gene expression in aged hypertensive rats, offering a sustainable byproduct-based approach to preventing CVD [63]. Collectively, these in vivo studies reveal that cacao exerts multifaceted cardiovascular benefits through anti-inflammatory, antioxidant, vasodilatory, anti-hypertrophic, and endothelial-enhancing mechanisms. This evidence highlights the therapeutic potential of cacao in preventing and mitigating CVD through its hemodynamic modulation and anti-inflammatory/antioxidant effects. A summary of the in vivo efficacy and mechanisms of action of cacao is presented in Table 3 (Ref. [50, 54, 55, 57, 58, 59, 60, 61, 62, 63]).

To bridge mechanistic insights and human outcomes, this section reviews how cacao flavanols perform in diverse clinical contexts, ranging from large-scale trials to targeted interventions in high-risk populations.

Although numerous clinical studies suggest cardiovascular benefits of cacao, the results remain inconsistent owing to substantial heterogeneity across study designs and populations. Variations in flavanol dosage, intervention duration, and cacao product formulations (e.g., extract, powder, and chocolate) contribute to divergent outcomes. For instance, short-term trials may fail to capture sustained physiological changes, whereas long-term studies often reveal more robust effects on vascular function and inflammatory markers. Differences in baseline health status—such as age, menopausal stage, obesity, or cardiometabolic disease—also influence individual responsiveness. Furthermore, inter-individual differences in gut microbiota composition and genetic polymorphisms affecting flavanol metabolism (e.g., catechol-O-methyltransferase (COMT), eNOS) can modify bioavailability and efficacy. In addition, the selection of endpoints (e.g., FMD, homeostasis model assessment-estimated insulin resistance, NT-proBNP, and cytokines) and analytical methods varies across trials, limiting direct comparability. These factors highlight the need for standardized intervention protocols, biomarker-driven stratification, and personalized approaches in future cacao-related clinical research.

Despite the comprehensive integration of in vitro, in vivo, and clinical evidence in this review, certain limitations should be acknowledged to improve clarity and future research planning.

Cacao and its byproducts, particularly CBSs, exert multifaceted cardioprotective effects via antioxidant, anti-inflammatory, endothelial-modulating, and lipid-regulating mechanisms. These effects are mediated through key molecular targets such as NF-$\kappa$B, Nrf2, eNOS, and ACE, contributing to improved vascular function, reduced oxidative stress, and metabolic homeostasis (Fig. 1). However, heterogeneity in cacao dosage, intervention duration, product formulation, and participant characteristics has led to inconsistent clinical outcomes. While some trials demonstrate significant improvements in vascular biomarkers, others report null effects, particularly in metabolically compromised populations or at sub-therapeutic flavanol doses. These inconsistencies emphasize the need for standardized intervention protocols, biomarker-guided endpoints, and personalized nutrition strategies. This review integrates mechanistic and clinical evidence, highlighting converging molecular pathways and emerging bioresources such as CBSs. It also identifies key knowledge gaps, including insufficient long-term data, limited understanding of host–microbiome interactions, and interindividual variability in response. To advance this field, future research should focus on: (1) conducting stratified randomized controlled trials in high-risk populations (e.g., PAD, heart failure, metabolic syndrome); (2) standardizing flavanol dose, form, and duration across studies; (3) integrating gut microbiome and pharmacogenomic profiling to understand variability in response; and (4) evaluating long-term effects on validated CVD biomarkers such as NT-proBNP, FMD, and TNF-$\alpha$.

Fig. 1.

Proposed mechanisms underlying the cardiovascular-protective effects of cacao bioactives. This figure highlights the key bioactive components of cacao—particularly polyphenols and theobromine—and their associated molecular mechanisms contributing to cardiovascular protection. Cacao enhances antioxidant defenses by upregulating Nrf2, heme oxygenase-1 (HO-1), and sirtuin 1 (SIRT1), while reducing circulating levels of C-reactive protein (CRP). It exerts anti-inflammatory effects by downregulating NF-$\kappa$B, MAPK, IL-6, and TNF-$\alpha$. In terms of vascular function, cacao promotes eNOS expression and NO production, while suppressing ACE and XO, thereby supporting vascular homeostasis. For lipid-lowering effects, cacao activates peroxisome proliferator activated receptor alpha (PPAR$\alpha$) and AMP-activated protein kinase (AMPK) pathways and inhibits low-density lipoprotein (LDL) oxidation, contributing to improved lipid metabolism. These molecular actions highlight the multifaceted role of cacao in mitigating cardiovascular disease risk by modulating oxidative stress, inflammation, endothelial dysfunction, and lipid dysregulation. “$\uparrow$”, upregulation or increased activity/expression; “$\downarrow$”, downregulation or decreased activity/expression. MAPK, mitogen-activated protein kinase; AMP, adenosine monophosphate.

ACE, angiotensin-converting enzyme; CBS, cacao bean shells; CVD, cardiovascular disease; CRP, C-reactive protein; cTn, cardiac troponin; FMD, flow mediated dilation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAD, peripheral artery disease.

YGL and JTH designed the study. YGL, JTH and HKC analyzed the data. YGL and JTH wrote the original draft. YGL, JTH, and HKC contributed to review and editing. All authors contributed to the critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Not applicable.

Graphical abstract within the review were designed under a license acquired from biorender.com.

This work was supported by the Main Research Program (E0210400-06) of the Korea Food Research Institute and funded by the Ministry of Science and ICT.

The authors declare no conflict of interest.

The authors acknowledge the use of ChatGPT-4.0 for spelling and grammar checks during the preparation of this manuscript. All content was subsequently reviewed and edited by the authors, who take full responsibility for the final version of the publication.